Skip to main content
DOCS logo

Doximity, Inc. (DOCS) Stock: Price, Forecast & Analyst Target

Doximity, Inc. (DOCS) — MoonshotScore 94/100 (Exceptional band), calculated Oct 5, 2026. Price $27.93 (-2.00%), as of the Oct 2, 2026 trading session; market cap $5.22B. Expected results Nov 5, 2026.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 7.59× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Nov 5, 2026

$27.93 −$0.57 (-2.00%) Market Cap $5.22B

Doximity, Inc. · DOCS · NYSE · Healthcare · Medical - Healthcare Information Services

Research dated 2026-09-13: Doximity operates a cloud-hosted platform where physicians, hospital systems, and pharmaceutical companies connect to deliver patient care, share medical information, and conduct professional collaboration. The company monetizes via subscription fees from healthcare organizations and marketing services to pharmaceutical clients; the key question is whether platform adoption and pricing sustain against rising competition and valuation multiples.

Price as of Oct 2, 2026

Key Statistics

94 of 100

MoonshotScore v2 · Doximity (DOCS)

Exceptional
Business Quality Elite (96)
Financial Safety Fortress (94)
Valuation Full (54)
Growth Durability Compounding (87)
Momentum Quiet (55)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and durable growth, with no real weak spot — fairly priced, so not a bargain entry. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.

  • quarterly revenue $157M (Q1 FY2027, quarter ended Jun 30, 2026)
  • EPS beat 6 of 8
  • Altman Z 20.67 · Piotroski F 6

Helping: business quality, balance-sheet strength, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DOCS (29 recorded, newest six shown)
RecordedScoreBand
93Exceptional
94Exceptional
94Exceptional
94Exceptional
95Exceptional
95Exceptional

The score was 94 in the stored Oct 4, 2026 snapshot and remains 94 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$27.93
Change on the day-2.00%
52-week range$17.15–$73.92
Market capitalisation$5.22B
Price / earnings (trailing)31.38
Shares traded on the day2.67M
Beta (volatility vs the S&P 500)1.25

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Sep 5, 2025 to Oct 2, 2026: low $19, high $74, latest $28. 4 reported quarters marked, 2 above and 2 below the recorded estimate. 1 other dated event marked. $74 $19 high $74 Nov 6, 2025 · Earnings results · reported above the recorded estimate · close $541Feb 5, 2026 · Earnings results · reported above the recorded estimate · close $282May 13, 2026 · Earnings results · reported below the recorded estimate · close $193Aug 6, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $274Aug 6, 2026 · Earnings results · reported below the recorded estimate · close $275 Sep 5, 2025 Oct 2, 2026 · $28 $69Sep 5, 2025$73Sep 19, 2025$73Oct 3, 2025$68Oct 17, 2025$66Oct 31, 2025$50Nov 14, 2025$51Nov 28, 2025$44Dec 12, 2025$44Dec 26, 2025$44Jan 9, 2026$41Jan 23, 2026$28Feb 6, 2026$26Feb 20, 2026$25Mar 6, 2026$24Mar 20, 2026$23Apr 2, 2026$25Apr 17, 2026$25May 1, 2026$19May 15, 2026$21May 29, 2026$20Jun 12, 2026$21Jun 26, 2026$22Jul 10, 2026$20Jul 24, 2026$27Aug 7, 2026$25Aug 21, 2026$26Sep 4, 2026$26Sep 18, 2026$28Oct 2, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • For Q2 '27 revenue, we expect a range of $170 million to $171 million, representing a midpoint of 1% year-over-year.

    Matthew Sonefeldt · Statement from

  • For adjusted EBITDA in Q2 '27, we expect a range of $80.5 million to $81.5 million, representing a 48% adjusted EBITDA margin at the midpoint.

    Matthew Sonefeldt · Statement from

Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.

Read management statements

Other perspectives

Council score for Doximity (DOCS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

9-Factor Breakdown

Revenue Growth Neutral
Gross Margin Strong
Operating Leverage Neutral
Cash Runway Neutral
R&D Intensity Neutral
Insider Activity Weak
Trading Liquidity Neutral
Price Momentum Negative
News Sentiment Neutral

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Strong
Revenue Growth Moderate
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Oct 5, 2026, except a card that shows its own read date.

Watch the DOCS film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is Doximity (DOCS), and what does it report?

Short answer · as of

Doximity's core offering is membership in a professional network serving licensed U.S. practitioners.

Research dated 2026-09-13.

Doximity's core offering is membership in a professional network serving licensed U.S. practitioners. Physicians access peer-to-peer messaging, remote consultation infrastructure, medical literature feeds, and career development tools at no direct cost; the company generates revenue by charging healthcare organizations for administrator accounts and data access, and by selling targeted marketing services to pharmaceutical companies. Operating cash flow reflects cash collected from these subscribers and services minus platform hosting, customer support, and sales expenses. The business model is durable because switching costs are high once adoption embeds clinical workflow.

Sources (as of 2026-09-13): Business description; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands)

2 · Latest results

What do the latest results show for Doximity (DOCS)?

Short answer · as of

The most recent reported quarter, Q1 FY2027, carried revenue of $157M.

Research dated 2026-09-13.

The most recent quarter showed revenue that exceeded estimates while earnings per share fell slightly short of consensus expectations. Operating cash flow declined from the prior period despite revenue growth, suggesting either timing of cash receipts or higher working capital deployment. Subscription revenue—the majority of total revenue—expanded and represents the most predictable revenue stream. Margins remain elevated, though year-over-year expansion paused from the acceleration of the previous period.

Sources (as of 2026-09-13): Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$156.62M Jun 30, 2026
Latest quarter · R&D
$38.48M Jun 30, 2026
Latest quarter · SG&A
$60.80M Jun 30, 2026
Latest quarter · FMP standardized operating result
$33.64M Jun 30, 2026
Where is operating spending going? — FMP standardized evidence
Period endRevenueR&DSG&AFMP standardized operating result
Jun 30, 2026$156.62M$38.48M$60.80M$33.64M
Mar 31, 2026$145.37M$39.11M$62.03M$24.83M
Dec 31, 2025$185.05M$34.59M$59.86M$71.90M
Sep 30, 2025$168.53M$30.20M$58.22M$63.68M

USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$156.62M Aug 6, 2026
Latest report · revenue estimate
$151.77M Aug 6, 2026
Latest report · revenue vs estimate
Above estimate Aug 6, 2026
Latest report · EPS vs estimate
Below estimate Aug 6, 2026
Did results meet expectations? — reported evidence
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Aug 6, 2026$156.62M$151.77M$0.2900$0.3030
May 13, 2026$145.37M$144.03M$0.2600$0.2800
Feb 5, 2026$185.05M$181.63M$0.4600$0.4400
Nov 6, 2025$168.53M$157.90M$0.4500$0.3787

Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2027$157M$24M$0.13 (diluted)
Q4 FY2026$145M$19M$0.10 (diluted)
Q3 FY2026$185M$62M$0.31 (diluted)
Q2 FY2026$169M$62M$0.31 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Doximity (DOCS)?

Short answer

Cash and short-term investments were $687.79M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $41.99M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Research dated 2026-09-13.

The balance sheet stands as a fortress with cash that exceeds total debt by an enormous margin, no meaningful interest-bearing obligations, and current assets covering liabilities by a multiple. Operating margins of this magnitude are exceptional and reflect software economics and network effects. The principal financial risk is erosion of competitive moat—either through new entrants fragmenting the physician community or existing platforms (health systems, Microsoft, Amazon) adding physician collaboration features at negligible incremental cost. Valuation multiples suggest markets are pricing in strong competitive headwinds.

Sources (as of 2026-09-13): Cash, investments and debt; Trailing twelve-month ratio set; Cash against market value

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$41.99M Jun 30, 2026
Previous quarter · operating cash flow
$109.52M Mar 31, 2026
How much cash does the business generate or use? — reported evidence
Period endOperating cash flowCapital expenditure (reported)
Jun 30, 2026$41.99M−$60,000
Mar 31, 2026$109.52M−$2.25M
Dec 31, 2025$60.89M−$2.37M
Sep 30, 2025$93.94M−$2.37M

Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.

USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.

4 · What to check next?

What should you watch next at Doximity (DOCS)?

Short answer · as of

The next earnings report is expected on Nov 5, 2026.

Research dated 2026-09-13.

Monitor subscription growth rates and pricing trends to confirm the core platform remains defensible. Watch for platform engagement metrics beyond the financial statements—monthly active users, message volume, time spent—to validate that network stickiness persists as the company matures. Recent analyst downgrades warrant attention as signals of consensus concern around growth deceleration or valuation exhaustion. Cash flow conversion remains the sanity check; if subscription revenue grows but cash collection slows, moat confidence should decline.

Sources (as of 2026-09-13): Analyst revenue and earnings estimates (average); Analyst actions, most recent per firm; Cash decline over the reported window

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. For Q2 '27 revenue, we expect a range of $170 million to $171 million, representing a midpoint of 1% year-over-year.

    Matthew Sonefeldt ·

  2. For adjusted EBITDA in Q2 '27, we expect a range of $80.5 million to $81.5 million, representing a 48% adjusted EBITDA margin at the midpoint.

    Matthew Sonefeldt ·

  3. For fiscal '27, we now expect a revised range of $309 million to $329 million, representing a 47% adjusted EBITDA margin at the midpoint.

    Matthew Sonefeldt ·

  4. We expect the majority of AI search revenue contracted to date to be recognized during Q3.

    Matthew Sonefeldt ·

5 · Peer comparison

How does Doximity compare with its peers?

Short answer

Doximity's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Research dated 2026-09-13.

Healthcare social platforms all compete for physician engagement and attention. Doximity's advantage rests on scale—largest physician network in the United States—and the installed base of health systems and pharma customers who have embedded its workflow into procurement and marketing processes. Newer competitors, particularly those backed by AWS or cloud infrastructure giants, carry lower friction cost structures but must build equivalent network density. This creates a race between Doximity's first-mover defensibility and the economics advantage of big tech entrants.

Sources (as of 2026-09-13): Business description; Revenue by segment; Distress and quality screens

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Doximity (DOCS) — this page$27.93$5.22B94
Hinge Health, Inc. (HNGE) Same industry, near in market value$97.67 Oct 2, 2026$7.56B93 5-pillar Oct 5, 2026
HealthEquity, Inc. (HQY) Same industry, near in market value$90.04 Oct 2, 2026$7.53B91 5-pillar Oct 5, 2026
Progyny, Inc. (PGNY) Same industry, near in market value$25.23 Oct 2, 2026$1.98B91 5-pillar Oct 5, 2026
BrightSpring Health Services, Inc. (BTSG) Same industry, near in market value$60.25 Oct 2, 2026$11.8B83 5-pillar Oct 5, 2026
Solventum Corporation (SOLV) Named competitor$87.85 Oct 2, 2026$15.2B61 5-pillar Oct 5, 2026
The Cooper Companies, Inc. (COO) Named competitor$56.91 Oct 2, 2026$11.1B39 5-pillar Oct 5, 2026
10x Genomics, Inc. (TXG) Same industry, near in market value$93.50 Oct 2, 2026$11.9B39 5-pillar Oct 5, 2026
Guardant Health, Inc. (GH) Named competitor$177.80 Oct 2, 2026$23.9B35 5-pillar Oct 5, 2026
Privia Health Group, Inc. (PRVA) Same industry, near in market value$20.30 Oct 2, 2026$2.56B35 5-pillar Oct 5, 2026
Viatris Inc. (VTRS) Named competitor$17.60 Oct 2, 2026$20.5B32 5-pillar Oct 5, 2026
HeartFlow, Inc. (HTFL) Same industry, near in market value$49.32 Oct 2, 2026$4.25B32 5-pillar Oct 5, 2026
GeneDx Holdings Corp. (WGS) Same industry, near in market value$73.09 Oct 2, 2026$2.18B32 5-pillar Oct 5, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$18.00 – $41.00
Consensus target
$27.00
Median target
$25.50

Consensus record · Captured .

Measured against a quoted price of $27.93 (as of Oct 2, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 30, 2026

Transactions
57
Identified insiders
9
Purchases
0
Sales
9
Other transactions
48

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
69.7% Period end Jun 30, 2026
Previous quarter · ownership
68.4% Prior to period end Jun 30, 2026
Reporting holders
379 Period end Jun 30, 2026
Previous quarter · holders
447 Prior to period end Jun 30, 2026
Who holds the shares? — reported evidence
Holders in provider snapshotShares
Blackrock, INC.14,307,116
Vanguard Portfolio Management LLC6,387,099
Vanguard Capital Management LLC5,977,433
D. E. Shaw & Co., INC.5,922,188
Two Sigma Investments, LP4,647,309

Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.

What has been published about Doximity (DOCS)?

Read these with our analysis →

Doximity Healthcare Stock: Key Questions Answered

Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.

Why is the subscription segment so much larger than service revenue?

Subscription revenue reflects fees charged to healthcare organizations and data licensing arrangements, which are recurring and predictable. Service revenue represents marketing services and other offerings that are episodic. The subscription model generates the business durability and earnings consistency; service revenue adds optionality.

Sources (as of 2026-09-13): Revenue by segment; Annual revenue and net result (USD millions); Trailing twelve-month ratio set

How can margins be this high if the company keeps losing estimated earnings?

Operating margins measure cash generation after costs; earnings per share reflects share dilution from equity compensation and one-time charges. The company is cash-generative and profitable by cash accounting, but equity compensation and non-cash items reduce reported net income per share.

Sources (as of 2026-09-13): Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters

Why did operating cash flow decline quarter-over-quarter?

The latest quarter's operating cash flow reflects timing of annual subscription billings and customer payment cycles rather than operational deterioration. Annual subscription renewals create large inflows in certain periods and smaller flows in others. The trailing-twelve-month cash conversion remains strong, and revenue growth continued.

Sources (as of 2026-09-13): Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)

Would a tech giant acquisition of a competitive platform be catastrophic?

New competition from scale-advantaged incumbents is the true structural risk. A Microsoft or Amazon platform feature targeting physicians would draw on existing healthcare relationships and infrastructure. Doximity's network effects and embedded workflow provide some defensibility, but pricing power would face downward pressure if credible alternatives materialized.

Sources (as of 2026-09-13): Trailing twelve-month ratio set; Analyst actions, most recent per firm; Business description

What is the DOCS stock price today?

The last price recorded on this page for Doximity, Inc. (DOCS) is $27.93, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the DOCS price target?

The analyst consensus price target for Doximity, Inc. (DOCS) is $27.00 (range $18.00 to $41.00, median $25.50), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources (as of 2026-09-13): Business description; Revenue by segment; Annual revenue and net result (USD millions)

Sources — records for every figure on this page (83 figures)

The 83 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

OFFICIAL — 2 facts from SEC filings and earnings calls

OFFICIAL facts used on this page
Fact IDFactValue as shownAs ofTierSource
prod.outlookManagement outlook — call excerptsMatthew Sonefeldt (Aug 6, 2026): For Q2 '27 revenue, we expect a range of $170 million to $171 million, representing a midpoint of 1% year-over-year. Matthew Sonefeldt (Aug 6, 2026): For adjusted EBITDA in Q2 '27, we expect a range of $80.5 million to $81.5 million, representing a 48% adjusted EBITDA margin at the midpoint. Matthew Sonefeldt (Aug 6, 2026): For fiscal '27, we now expect a revised range of $309 million to $329 million, representing a 47% adjusted EBITDA margin at the midpoint. Matthew Sonefeldt (Aug 6, 2026): We expect the majority of AI search revenue contracted to date to be recognized during Q3.OFFICIALCompany earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording.
id.hqSEC filing business address500 Third Street, Suite 510, SAN Francisco, CA, 94107OFFICIALSEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "500, 3rd Street, San Francisco, CA, 94107, US".

FMP — 74 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.nextNext earnings dateNov 5, 2026FMPFinancial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it.
px.lastLatest provided price$27.93FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T00:24:39.304Z.
px.changeChange on the day-2.00%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$5.22BFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:02.000Z. Captured from FMP at 2026-10-05T00:24:38.363Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars−$0.57FMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q1 FY2027$157MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
px.range5252-week range$17.15–$73.92FMPFinancial Modeling Prep (FMP) quote
px.pePrice / earnings (trailing)31.38FMPFinancial Modeling Prep (FMP) · quote
px.volumeShares traded on the day2.67MFMPFinancial Modeling Prep (FMP) · quote
px.betaBeta1.25FMPFinancial Modeling Prep (FMP) company profile
id.ceoChief executiveJeffrey A. TangneyFMPFinancial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it.
id.employeesEmployees880FMPFinancial Modeling Prep (FMP) employee count, from the company's filing
fin.annualRevenue and net result by fiscal year5 fiscal years, FY2022 through FY2026: FY2022 revenue $343.55M, net result $154.78M; FY2023 revenue $419.05M, net result $112.82M; FY2024 revenue $475.42M, net result $147.58M; FY2025 revenue $570.40M, net result $223.19M; FY2026 revenue $644.86M, net result $196.05MFMPFinancial Modeling Prep (FMP), from the company's 10-K income statements
fin.rev_mixReported revenue segmentsSubscription $608.41M · Service, Other $36.45MFMPFinancial Modeling Prep (FMP) revenue segmentation, from the company's 10-K
fin.gross_marginGross margin (trailing twelve months)88.1%FMPFinancial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero.
fin.q_table.depth.2026-06-30.revenue_kRevenue — period end 2026-06-30$156.62MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2026-06-30.rd_kR&D — period end 2026-06-30$38.48MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2026-06-30.sga_kSG&A — period end 2026-06-30$60.80MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2026-06-30.operating_result_kFMP standardized operating result — period end 2026-06-30$33.64MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2026-03-31.revenue_kRevenue — period end 2026-03-31$145.37MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2026-03-31.rd_kR&D — period end 2026-03-31$39.11MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2026-03-31.sga_kSG&A — period end 2026-03-31$62.03MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2026-03-31.operating_result_kFMP standardized operating result — period end 2026-03-31$24.83MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2025-12-31.revenue_kRevenue — period end 2025-12-31$185.05MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2025-12-31.rd_kR&D — period end 2025-12-31$34.59MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2025-12-31.sga_kSG&A — period end 2025-12-31$59.86MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2025-12-31.operating_result_kFMP standardized operating result — period end 2025-12-31$71.90MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2025-09-30.revenue_kRevenue — period end 2025-09-30$168.53MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2025-09-30.rd_kR&D — period end 2025-09-30$30.20MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2025-09-30.sga_kSG&A — period end 2025-09-30$58.22MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
fin.q_table.depth.2025-09-30.operating_result_kFMP standardized operating result — period end 2025-09-30$63.68MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note
earn.history.depth.2026-08-06.revenue_actualRevenue · reported — report date 2026-08-06$156.62MReport date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-08-06.revenue_estimatedRevenue · estimate — report date 2026-08-06$151.77MReport date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-08-06.eps_actualEPS · reported — report date 2026-08-06$0.2900Report date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-08-06.eps_estimatedEPS · estimate — report date 2026-08-06$0.3030Report date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-05-13.revenue_actualRevenue · reported — report date 2026-05-13$145.37MReport date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-05-13.revenue_estimatedRevenue · estimate — report date 2026-05-13$144.03MReport date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-05-13.eps_actualEPS · reported — report date 2026-05-13$0.2600Report date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-05-13.eps_estimatedEPS · estimate — report date 2026-05-13$0.2800Report date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-02-05.revenue_actualRevenue · reported — report date 2026-02-05$185.05MReport date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-02-05.revenue_estimatedRevenue · estimate — report date 2026-02-05$181.63MReport date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-02-05.eps_actualEPS · reported — report date 2026-02-05$0.4600Report date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2026-02-05.eps_estimatedEPS · estimate — report date 2026-02-05$0.4400Report date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2025-11-06.revenue_actualRevenue · reported — report date 2025-11-06$168.53MReport date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2025-11-06.revenue_estimatedRevenue · estimate — report date 2025-11-06$157.90MReport date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2025-11-06.eps_actualEPS · reported — report date 2025-11-06$0.4500Report date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
earn.history.depth.2025-11-06.eps_estimatedEPS · estimate — report date 2025-11-06$0.3787Report date · FMPFinancial Modeling Prep (FMP) earnings — Earnings-history note
fin.q_tableQuarterly income statement4 quarters through Q1 FY2027FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed
fin.cash_investmentsCash and short-term investments$687.79MFMPFinancial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review.
fin.opcf_latestLatest-quarter operating cash flow$41.99MFMPFinancial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate.
fin.long_term_investmentsLong-term investments (classification unverified)$0.00FMPFinancial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability.
fin.total_debtTotal debt$9.67MFMPFinancial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability.
fin.price_to_bookPrice to book value5.57×FMPFinancial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero.
fin.opcf.depth.2026-06-30.operating_cash_flow_mOperating cash flow — period end 2026-06-30$41.99MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note
fin.opcf.depth.2026-03-31.operating_cash_flow_mOperating cash flow — period end 2026-03-31$109.52MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note
fin.opcf.depth.2026-06-30.capex_mCapital expenditure (reported) — period end 2026-06-30−$60,000Period end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note
fin.opcf.depth.2026-03-31.capex_mCapital expenditure (reported) — period end 2026-03-31−$2.25MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note
fin.opcf.depth.2025-12-31.operating_cash_flow_mOperating cash flow — period end 2025-12-31$60.89MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note
fin.opcf.depth.2025-12-31.capex_mCapital expenditure (reported) — period end 2025-12-31−$2.37MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note
fin.opcf.depth.2025-09-30.operating_cash_flow_mOperating cash flow — period end 2025-09-30$93.94MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note
fin.opcf.depth.2025-09-30.capex_mCapital expenditure (reported) — period end 2025-09-30−$2.37MPeriod end · FMPFinancial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note
earn.pt_rangeAnalyst price target, low to high$18.00 – $41.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied
earn.pt_consensusConsensus analyst price target$27.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied
earn.pt_medianMedian analyst price target$25.50FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied
own.insidersInsider transactions via FMP57 transactions · 0 purchases, 9 sales, 48 other transactions · 9 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 30, 2026FMPFinancial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
own.institutions.depth.ownership_pctInstitutional ownership69.7%FMPFinancial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026
own.institutions.depth.ownership_pct_previous_quarterPrevious quarter · ownership68.4%FMPFinancial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026
own.institutions.depth.holdersReporting holders379FMPFinancial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026
own.institutions.depth.holders_previous_quarterPrevious quarter · holders447FMPFinancial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026
own.top_holders.depth.holder_0.sharesBlackrock, INC. — shares in provider snapshot14,307,116FMPFinancial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied.
own.top_holders.depth.holder_1.sharesVanguard Portfolio Management LLC — shares in provider snapshot6,387,099FMPFinancial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied.
own.top_holders.depth.holder_2.sharesVanguard Capital Management LLC — shares in provider snapshot5,977,433FMPFinancial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied.
own.top_holders.depth.holder_3.sharesD. E. Shaw & Co., INC. — shares in provider snapshot5,922,188FMPFinancial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied.
own.top_holders.depth.holder_4.sharesTwo Sigma Investments, LP — shares in provider snapshot4,647,309FMPFinancial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied.

UNRECORDED — 2 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.historyReported versus estimated, recent quartersEPS beat 6 of 8UNRECORDEDStored earnings-history observation — Captured 2026-10-02 · Expired observation
fin.scoresDistress and quality screensAltman Z 20.67 · Piotroski F 6UNRECORDEDStored financial-scores observation — Captured 2026-10-04 · Expired observation

COMPUTED — 3 facts from our arithmetic, formula restated

COMPUTED facts used on this page
Fact IDFactValue as shownAs ofTierSource
fin.mcap_to_cashMarket value per dollar of cash and short-term investments7.59×—COMPUTEDComputed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $687.79M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio.
earn.history.depth.2026-08-06.revenue_actual.comparisonLatest report · revenue vs estimateAbove estimateReport date · COMPUTEDComputed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($156.62M) with the recorded estimate ($151.77M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns.
earn.history.depth.2026-08-06.eps_actual.comparisonLatest report · EPS vs estimateBelow estimateReport date · COMPUTEDComputed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.2900) with the recorded estimate ($0.3030) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns.

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v294 of 100 · Exceptional · pillars 96 / 94 / 54 / 87 / 55OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement94 (stored snapshot Oct 4, 2026) → 94 (current publication computed Oct 5, 2026) (0)OURSStock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive.

Fact-family notes

  1. Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs: fin.q_table.depth.2026-06-30.revenue_k, fin.q_table.depth.2026-06-30.rd_k, fin.q_table.depth.2026-06-30.sga_k, fin.q_table.depth.2026-06-30.operating_result_k, fin.q_table.depth.2026-03-31.revenue_k, fin.q_table.depth.2026-03-31.rd_k, fin.q_table.depth.2026-03-31.sga_k, fin.q_table.depth.2026-03-31.operating_result_k, fin.q_table.depth.2025-12-31.revenue_k, fin.q_table.depth.2025-12-31.rd_k, fin.q_table.depth.2025-12-31.sga_k, fin.q_table.depth.2025-12-31.operating_result_k, fin.q_table.depth.2025-09-30.revenue_k, fin.q_table.depth.2025-09-30.rd_k, fin.q_table.depth.2025-09-30.sga_k, fin.q_table.depth.2025-09-30.operating_result_k.
  2. Earnings-history note. Source series as of 2026-08-06. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs: earn.history.depth.2026-08-06.revenue_actual, earn.history.depth.2026-08-06.revenue_estimated, earn.history.depth.2026-08-06.revenue_actual.comparison, earn.history.depth.2026-08-06.eps_actual.comparison, earn.history.depth.2026-08-06.eps_actual, earn.history.depth.2026-08-06.eps_estimated, earn.history.depth.2026-05-13.revenue_actual, earn.history.depth.2026-05-13.revenue_estimated, earn.history.depth.2026-05-13.eps_actual, earn.history.depth.2026-05-13.eps_estimated, earn.history.depth.2026-02-05.revenue_actual, earn.history.depth.2026-02-05.revenue_estimated, earn.history.depth.2026-02-05.eps_actual, earn.history.depth.2026-02-05.eps_estimated, earn.history.depth.2025-11-06.revenue_actual, earn.history.depth.2025-11-06.revenue_estimated, earn.history.depth.2025-11-06.eps_actual, earn.history.depth.2025-11-06.eps_estimated.
  3. Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs: fin.opcf.depth.2026-06-30.operating_cash_flow_m, fin.opcf.depth.2026-03-31.operating_cash_flow_m, fin.opcf.depth.2026-06-30.capex_m, fin.opcf.depth.2026-03-31.capex_m, fin.opcf.depth.2025-12-31.operating_cash_flow_m, fin.opcf.depth.2025-12-31.capex_m, fin.opcf.depth.2025-09-30.operating_cash_flow_m, fin.opcf.depth.2025-09-30.capex_m.
Published
Research standards
Methodology · Editorial policy · Corrections

Sources used for research written 2026-09-13

Historical evidence preserved with this analysis. Current figures are listed separately above.

EvidenceCaptured valueSource dateSource typeSource
Business description
Doximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers. Its primary clientele consists of pharmaceutical companies and healthcare organizations. Established in 2010, the entity initially operated as 3MD Communications, Inc. before rebranding to Doximity, Inc. in June of that year. The company's corporate headquarters are situated in San Francisco, California.
2026-09-13FMPFinancial Modeling Prep (FMP) company profile
Revenue by segment
Subscription: $608.41M; Service, Other: $36.45M
2026-03-31FMPFinancial Modeling Prep (FMP) revenue segmentation, from the company's 10-K
Annual revenue and net result (USD millions)
Captured record · 5 entries
  • FY2026 — R&D: $130.70M, Revenue: $644.86M, Period end: 2026-03-31, Net result: $196.05M
  • FY2025 — R&D: $93.04M, Revenue: $570.40M, Period end: 2025-03-31, Net result: $223.19M
  • FY2024 — R&D: $81.98M, Revenue: $475.42M, Period end: 2024-03-31, Net result: $147.58M
  • FY2023 — R&D: $80.19M, Revenue: $419.05M, Period end: 2023-03-31, Net result: $112.82M
  • FY2022 — R&D: $62.35M, Revenue: $343.55M, Period end: 2022-03-31, Net result: $154.78M
2026-03-31FMPFinancial Modeling Prep (FMP), from the company's 10-K income statements
Operating cash flow by quarter (USD millions)
Captured record · 8 entries
  • Quarter ended 2026-06-30 — Capital expenditure: -$60,000, Operating cash flow: $41.99M
  • Quarter ended 2026-03-31 — Capital expenditure: -$2.25M, Operating cash flow: $109.52M
  • Quarter ended 2025-12-31 — Capital expenditure: -$2.37M, Operating cash flow: $60.89M
  • Quarter ended 2025-09-30 — Capital expenditure: -$2.37M, Operating cash flow: $93.94M
  • Quarter ended 2025-06-30 — Capital expenditure: -$1.97M, Operating cash flow: $62.10M
  • Quarter ended 2025-03-31 — Capital expenditure: -$1.51M, Operating cash flow: $98.49M
  • Quarter ended 2024-12-31 — Capital expenditure: -$1.77M, Operating cash flow: $65.19M
  • Quarter ended 2024-09-30 — Capital expenditure: -$1.54M, Operating cash flow: $68.35M
2026-06-30FMPFinancial Modeling Prep (FMP), from the company's 10-Q cash-flow statements
Quarterly income statement (USD thousands)
Captured record · 8 entries
  • Quarter ended 2026-06-30 — EPS: $0.13 per share, R&D: $38.48M, SG&A: $60.80M, EPS basic: $0.13 per share, EPS basis: diluted, Revenue: $156.62M, EPS diluted: $0.13 per share, Net result: $24.32M, Gross profit: $132.93M, Operating result: $33.64M
  • Quarter ended 2026-03-31 — EPS: $0.1 per share, R&D: $39.11M, SG&A: $62.03M, EPS basic: $0.1 per share, EPS basis: diluted, Revenue: $145.37M, EPS diluted: $0.1 per share, Net result: $19.11M, Gross profit: $125.97M, Operating result: $24.83M
  • Quarter ended 2025-12-31 — EPS: $0.31 per share, R&D: $34.59M, SG&A: $59.86M, EPS basic: $0.33 per share, EPS basis: diluted, Revenue: $185.05M, EPS diluted: $0.31 per share, Net result: $61.56M, Gross profit: $166.35M, Operating result: $71.90M
  • Quarter ended 2025-09-30 — EPS: $0.31 per share, R&D: $30.20M, SG&A: $58.22M, EPS basic: $0.33 per share, EPS basis: diluted, Revenue: $168.53M, EPS diluted: $0.31 per share, Net result: $62.06M, Gross profit: $152.10M, Operating result: $63.68M
  • Quarter ended 2025-06-30 — EPS: $0.27 per share, R&D: $26.80M, SG&A: $48.80M, EPS basic: $0.28 per share, EPS basis: diluted, Revenue: $145.91M, EPS diluted: $0.27 per share, Net result: $53.32M, Gross profit: $130.12M, Operating result: $54.52M
  • Quarter ended 2025-03-31 — EPS: $0.31 per share, R&D: $24.80M, SG&A: $50.34M, EPS basic: $0.33 per share, EPS basis: diluted, Revenue: $138.29M, EPS diluted: $0.31 per share, Net result: $62.46M, Gross profit: $123.82M, Operating result: $48.68M
  • Quarter ended 2024-12-31 — EPS: $0.37 per share, R&D: $22.42M, SG&A: $52.08M, EPS basic: $0.4 per share, EPS basis: diluted, Revenue: $168.60M, EPS diluted: $0.37 per share, Net result: $75.20M, Gross profit: $154.42M, Operating result: $79.92M
  • Quarter ended 2024-09-30 — EPS: $0.22 per share, R&D: $23.24M, SG&A: $44.47M, EPS basic: $0.24 per share, EPS basis: diluted, Revenue: $136.83M, EPS diluted: $0.22 per share, Net result: $44.15M, Gross profit: $123.16M, Operating result: $53.14M
2026-06-30FMPFinancial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements
Reported versus estimated, last 8 quarters
Captured record · 8 entries
  • Reported 2026-08-06 — EPS actual: $0.29 per share, EPS estimated: $0.303 per share, Revenue actual: $156.62M, Revenue estimated: $151.77M
  • Reported 2026-05-13 — EPS actual: $0.26 per share, EPS estimated: $0.28 per share, Revenue actual: $145.37M, Revenue estimated: $144.03M
  • Reported 2026-02-05 — EPS actual: $0.46 per share, EPS estimated: $0.44 per share, Revenue actual: $185.05M, Revenue estimated: $181.63M
  • Reported 2025-11-06 — EPS actual: $0.45 per share, EPS estimated: $0.3787 per share, Revenue actual: $168.53M, Revenue estimated: $157.90M
  • Reported 2025-08-07 — EPS actual: $0.36 per share, EPS estimated: $0.3016 per share, Revenue actual: $145.91M, Revenue estimated: $139.53M
  • Reported 2025-05-15 — EPS actual: $0.38 per share, EPS estimated: $0.2716 per share, Revenue actual: $138.29M, Revenue estimated: $133.73M
  • Reported 2025-02-06 — EPS actual: $0.45 per share, EPS estimated: $0.31 per share, Revenue actual: $168.60M, Revenue estimated: $152.82M
  • Reported 2024-11-07 — EPS actual: $0.3 per share, EPS estimated: $0.25 per share, Revenue actual: $136.83M, Revenue estimated: $127.13M
2026-08-06FMPFinancial Modeling Prep (FMP) earnings
Cash, investments and debt
Total debt: $9.67M; Liquidity basis: cash and short-term investments; Total liabilities: $167.78M; Cash and short-term investments: $687.79M; Cash and investments: $687.80M; Long-term investments: $0; Long-term investments classification: unclassified

Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability.

2026-06-30FMPFinancial Modeling Prep (FMP), from the company's balance sheet
Trailing twelve-month ratio set
Quick ratio: 6.08; Current ratio: 6.08; Debt to equity: 0.01; Net margin: 25.5%; Gross margin: 88.1%; Operating margin: 29.6%; Return on assets: 15.4%; Return on equity: 17%

Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero.

2026-09-13FMPFinancial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm
Cash against market value
As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $678.10M; Total debt: $9.70M; Cash and investments: $687.80M

Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them.

2026-06-30COMPUTEDComputed from the balance sheet and the latest market capitalization
Analyst revenue and earnings estimates (average)
Captured record · 4 entries
  • FY2028 — EPS average: $1.55 per share, Revenue average: $720.85M, Revenue low: $704.22M, Revenue high: $742.13M, Analysts (revenue): 14
  • FY2029 — EPS average: $1.83 per share, Revenue average: $777.93M, Revenue low: $754.69M, Revenue high: $822.46M, Analysts (revenue): 7
  • FY2030 — EPS average: $1.93 per share, Revenue average: $827.95M, Revenue low: $810.41M, Revenue high: $848.65M, Analysts (revenue): 3
  • FY2031 — EPS average: $2.05 per share, Revenue average: $863.10M, Revenue low: $844.82M, Revenue high: $884.67M, Analysts (revenue): 4
2026-09-13FMPFinancial Modeling Prep (FMP) analyst estimates
Analyst actions, most recent per firm
Captured record · 10 entries
  • 2026-09-08 — Firm: Freedom Capital Markets, Action: downgrade, Rating: Hold, Previous rating: Buy
  • 2026-08-21 — Firm: Barclays, Action: maintain, Rating: Equal Weight, Previous rating: Equal Weight
  • 2026-08-13 — Firm: Truist Securities, Action: maintain, Rating: Hold, Previous rating: Hold
  • 2026-08-10 — Firm: Wells Fargo, Action: downgrade, Rating: Underweight, Previous rating: Equal Weight
  • 2026-08-07 — Firm: Piper Sandler, Action: maintain, Rating: Overweight, Previous rating: Overweight
  • 2026-08-07 — Firm: Evercore ISI Group, Action: maintain, Rating: In Line, Previous rating: In Line
  • 2026-08-07 — Firm: JP Morgan, Action: maintain, Rating: Neutral, Previous rating: Neutral
  • 2026-06-29 — Firm: B of A Securities, Action: downgrade, Rating: Underperform, Previous rating: Buy
  • 2026-05-15 — Firm: Goldman Sachs, Action: maintain, Rating: Neutral, Previous rating: Neutral
  • 2026-05-14 — Firm: BTIG, Action: downgrade, Rating: Neutral, Previous rating: Buy

One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not.

2026-09-08FMPFinancial Modeling Prep (FMP) analyst grades
Cash decline over the reported window
To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $687.80M; Decline: $117.80M; Opening balance: $805.60M; Average change per period: $16.80M

Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length.

2026-06-30COMPUTEDComputed from reported balances
Distress and quality screens
Altman Z-score: 19.09; Piotroski F-score: 6

Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading.

2026-09-13FMPFinancial Modeling Prep (FMP) financial scores
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.